Moxifloxacina Aurobindo (Moxifloxacin Hydrochloride)

Moxifloxacin blocks bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. By preventing the resealing of DNA strands, it leads to bacterial cell death and provides broad‑spectrum antibacterial activity.

The dose of Moxifloxacina Aurobindo is determined by the prescribing clinician based on the infection type, severity, patient age, renal and hepatic function, and local treatment guidelines. Patients should follow the exact regimen provided by their healthcare professional.

The pregnancy category for moxifloxacin is not definitively established. Because fluoroquinolones may affect fetal cartilage development, they are generally avoided unless the potential benefit outweighs the risk. Breastfeeding mothers should consult a physician, as the drug can be excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Moxifloxacin offers a broader spectrum against atypical respiratory pathogens and a longer half‑life, allowing once‑daily dosing for many infections. Compared with older fluoroquinolones such as ciprofloxacin, it has enhanced activity against Gram‑positive organisms and a lower propensity for certain drug‑resistance mechanisms.

Moxifloxacina Aurobindo tablets should be stored at ambient temperature below 25 °C, in the original packaging, and protected from moisture and direct sunlight. Do not store in bathrooms or near heat sources.

The medication is taken orally, usually with a full glass of water. It can be taken with or without food, but antacids containing aluminum or magnesium should be spaced at least two hours apart to avoid reduced absorption.

Serious risks include tendon rupture or tendinitis, QT‑interval prolongation leading to potentially fatal arrhythmias, severe allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome, Clostridioides difficile‑associated colitis, hepatic toxicity, and peripheral neuropathy. Patients should seek immediate medical attention if they experience related symptoms.

Moxifloxacina Aurobindo is contraindicated in individuals with a known hypersensitivity to moxifloxacin or any fluoroquinolone, those with a history of tendon disorders related to fluoroquinolone use, and patients taking other QT‑prolonging agents when the risk of arrhythmia is high. Caution is also advised for patients with severe renal or hepatic impairment.